Answers are grounded in this paper and cite their sources.
Objective: A cutting edge potential treatment of type 2 diabetes (T2D) is the use of cellular therapy. One recent method is the use of combination of stromal vascular fraction (SVF) and autologous activated platelet-rich plasma (aaPRP). This study is aimed to evaluate the efficacy of SVF combined with aaPRP to treat T2D. Materials and methods: Patients with T2D who underwent SVF and aaPRP treatment were recruited in this study. The lipoaspirate was digested by H-Remedy enzyme and centrifuged to isolate SVF. Blood was drawn from the patients and the aaPRP was isolated. The combination of autologous SVF and aaPRP was administered intravenously to each patient. Patients’ 1-month and 3-month post therapy HbA1c level were statistically analyzed to their baseline level. Results: A total of 39 patients, 28 male and 11 female, with T2D with mean age of 59±11 years and baseline HbA1c of 8.31 g/dL were included in this study. Combination of SVF and aaPRP treatment in T2D resulted in a statistically significant decrease in HbA1c level to 7.58 g/dL at 1 month and to 7.63 g/dL at 3 months posttherapy, while a decrease in HbA1c was still observed at 6 and 12 months after therapy. Conclusions: SVF combined with aaPRP may have potential to reduce HbA1c levels in patients with T2D. Further research is needed to confirm the findings of our research.
No takes yet. Share an insight, caveat, or question.
Karina et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: